Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia

  1. Rautenberg, Christina
  2. Stölzel, Friedrich ORCID logo
  3. Röllig, Christoph
  4. Stelljes, Matthias
  5. Gaidzik, Verena
  6. Lauseker, Michael ORCID logo
  7. Kriege, Oliver
  8. Verbeek, Mareike
  9. Unglaub, Julia Marie
  10. Thol, Felicitas
  11. Krause, Stefan ORCID logo
  12. Hänel, Mathias
  13. Neuerburg, Charlotte
  14. Vucinic, Vladan
  15. Jehn, Christian-Friedrich
  16. Severmann, Julia
  17. Wass, Maxi
  18. Fransecky, Lars
  19. Chemnitz, Jens
  20. Holtick, Udo
  21. Schäfer-Eckart, Kerstin
  22. Schröder, Josephine
  23. Kraus, Sabrina
  24. Krüger, William
  25. Kaiser, Ulrich
  26. Scholl, Sebastian
  27. Koch, Kathrin
  28. Henning, Lea
  29. Kobbe, Guido
  30. Haas, Rainer
  31. Alakel, Nael
  32. Röhnert, Maximilian-Alexander
  33. Sockel, Katja ORCID logo
  34. Hanoun, Maher
  35. Platzbecker, Uwe
  36. Holderried, Tobias A. W.
  37. Morgner, Anke
  38. Heuser, Michael ORCID logo
  39. Sauer, Tim
  40. Götze, Katharina S.
  41. Wagner-Drouet, Eva
  42. Döhner, Konstanze
  43. Döhner, Hartmut
  44. Schliemann, Christoph
  45. Schetelig, Johannes
  46. Bornhäuser, Martin
  47. Germing, Ulrich
  48. Schroeder, Thomas ORCID logo
  49. Middeke, Jan Moritz ORCID logo

Download
s41408-021-00558-5.pdf 1,17MB
WeightNameValue
1000 Titel
  • Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia
1000 Autor/in
  1. Rautenberg, Christina |
  2. Stölzel, Friedrich |
  3. Röllig, Christoph |
  4. Stelljes, Matthias |
  5. Gaidzik, Verena |
  6. Lauseker, Michael |
  7. Kriege, Oliver |
  8. Verbeek, Mareike |
  9. Unglaub, Julia Marie |
  10. Thol, Felicitas |
  11. Krause, Stefan |
  12. Hänel, Mathias |
  13. Neuerburg, Charlotte |
  14. Vucinic, Vladan |
  15. Jehn, Christian-Friedrich |
  16. Severmann, Julia |
  17. Wass, Maxi |
  18. Fransecky, Lars |
  19. Chemnitz, Jens |
  20. Holtick, Udo |
  21. Schäfer-Eckart, Kerstin |
  22. Schröder, Josephine |
  23. Kraus, Sabrina |
  24. Krüger, William |
  25. Kaiser, Ulrich |
  26. Scholl, Sebastian |
  27. Koch, Kathrin |
  28. Henning, Lea |
  29. Kobbe, Guido |
  30. Haas, Rainer |
  31. Alakel, Nael |
  32. Röhnert, Maximilian-Alexander |
  33. Sockel, Katja |
  34. Hanoun, Maher |
  35. Platzbecker, Uwe |
  36. Holderried, Tobias A. W. |
  37. Morgner, Anke |
  38. Heuser, Michael |
  39. Sauer, Tim |
  40. Götze, Katharina S. |
  41. Wagner-Drouet, Eva |
  42. Döhner, Konstanze |
  43. Döhner, Hartmut |
  44. Schliemann, Christoph |
  45. Schetelig, Johannes |
  46. Bornhäuser, Martin |
  47. Germing, Ulrich |
  48. Schroeder, Thomas |
  49. Middeke, Jan Moritz |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-10-04
1000 Erschienen in
1000 Quellenangabe
  • 11(10):164
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1038/s41408-021-00558-5 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8490353/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • To investigate the efficacy and toxicities of CPX-351 outside a clinical trial, we analyzed 188 patients (median age 65 years, range 26-80) treated for therapy-related acute myeloid leukemia (t-AML, 29%) or AML with myelodysplasia-related changes (AML-MRC, 70%). Eighty-six percent received one, 14% two induction cycles, and 10% received consolidation (representing 22% of patients with CR/CRi) with CPX-351. Following induction, CR/CRi rate was 47% including 64% of patients with available information achieving measurable residual disease (MRD) negativity (<10
1000 Sacherschließung
lokal Female [MeSH]
lokal Follow-Up Studies [MeSH]
lokal Aged, 80 and over [MeSH]
lokal Allografts [MeSH]
lokal Leukaemia
lokal Aged [MeSH]
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Daunorubicin/administration
lokal Leukemia, Myeloid, Acute/mortality [MeSH]
lokal Hematopoietic Stem Cell Transplantation [MeSH]
lokal Leukemia, Myeloid, Acute/blood [MeSH]
lokal Middle Aged [MeSH]
lokal Survival Rate [MeSH]
lokal Article
lokal Male [MeSH]
lokal Haematological cancer
lokal Disease-Free Survival [MeSH]
lokal Neoplasm, Residual [MeSH]
lokal Cytarabine/administration
lokal Leukemia, Myeloid, Acute/therapy [MeSH]
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/UmF1dGVuYmVyZywgQ2hyaXN0aW5h|https://orcid.org/0000-0003-0653-5332|https://frl.publisso.de/adhoc/uri/UsO2bGxpZywgQ2hyaXN0b3Bo|https://frl.publisso.de/adhoc/uri/U3RlbGxqZXMsIE1hdHRoaWFz|https://frl.publisso.de/adhoc/uri/R2FpZHppaywgVmVyZW5h|https://orcid.org/0000-0002-6662-7127|https://frl.publisso.de/adhoc/uri/S3JpZWdlLCBPbGl2ZXI=|https://frl.publisso.de/adhoc/uri/VmVyYmVlaywgTWFyZWlrZQ==|https://frl.publisso.de/adhoc/uri/VW5nbGF1YiwgSnVsaWEgTWFyaWU=|https://frl.publisso.de/adhoc/uri/VGhvbCwgRmVsaWNpdGFz|https://orcid.org/0000-0002-5259-4651|https://frl.publisso.de/adhoc/uri/SMOkbmVsLCBNYXRoaWFz|https://frl.publisso.de/adhoc/uri/TmV1ZXJidXJnLCBDaGFybG90dGU=|https://frl.publisso.de/adhoc/uri/VnVjaW5pYywgVmxhZGFu|https://frl.publisso.de/adhoc/uri/SmVobiwgQ2hyaXN0aWFuLUZyaWVkcmljaA==|https://frl.publisso.de/adhoc/uri/U2V2ZXJtYW5uLCBKdWxpYQ==|https://frl.publisso.de/adhoc/uri/V2FzcywgTWF4aQ==|https://frl.publisso.de/adhoc/uri/RnJhbnNlY2t5LCBMYXJz|https://frl.publisso.de/adhoc/uri/Q2hlbW5pdHosIEplbnM=|https://frl.publisso.de/adhoc/uri/SG9sdGljaywgVWRv|https://frl.publisso.de/adhoc/uri/U2Now6RmZXItRWNrYXJ0LCBLZXJzdGlu|https://frl.publisso.de/adhoc/uri/U2NocsO2ZGVyLCBKb3NlcGhpbmU=|https://frl.publisso.de/adhoc/uri/S3JhdXMsIFNhYnJpbmE=|https://frl.publisso.de/adhoc/uri/S3LDvGdlciwgV2lsbGlhbQ==|https://frl.publisso.de/adhoc/uri/S2Fpc2VyLCBVbHJpY2g=|https://frl.publisso.de/adhoc/uri/U2Nob2xsLCBTZWJhc3RpYW4=|https://frl.publisso.de/adhoc/uri/S29jaCwgS2F0aHJpbg==|https://frl.publisso.de/adhoc/uri/SGVubmluZywgTGVh|https://frl.publisso.de/adhoc/uri/S29iYmUsIEd1aWRv|https://frl.publisso.de/adhoc/uri/SGFhcywgUmFpbmVy|https://frl.publisso.de/adhoc/uri/QWxha2VsLCBOYWVs|https://frl.publisso.de/adhoc/uri/UsO2aG5lcnQsIE1heGltaWxpYW4tQWxleGFuZGVy|https://orcid.org/0000-0003-1732-7299|https://frl.publisso.de/adhoc/uri/SGFub3VuLCBNYWhlcg==|https://frl.publisso.de/adhoc/uri/UGxhdHpiZWNrZXIsIFV3ZQ==|https://frl.publisso.de/adhoc/uri/SG9sZGVycmllZCwgVG9iaWFzIEEuIFcu|https://frl.publisso.de/adhoc/uri/TW9yZ25lciwgQW5rZQ==|https://orcid.org/0000-0001-5318-9044|https://frl.publisso.de/adhoc/uri/U2F1ZXIsIFRpbQ==|https://frl.publisso.de/adhoc/uri/R8O2dHplLCBLYXRoYXJpbmEgUy4=|https://frl.publisso.de/adhoc/uri/V2FnbmVyLURyb3VldCwgRXZh|https://frl.publisso.de/adhoc/uri/RMO2aG5lciwgS29uc3Rhbnpl|https://frl.publisso.de/adhoc/uri/RMO2aG5lciwgSGFydG11dA==|https://frl.publisso.de/adhoc/uri/U2NobGllbWFubiwgQ2hyaXN0b3Bo|https://frl.publisso.de/adhoc/uri/U2NoZXRlbGlnLCBKb2hhbm5lcw==|https://frl.publisso.de/adhoc/uri/Qm9ybmjDpHVzZXIsIE1hcnRpbg==|https://frl.publisso.de/adhoc/uri/R2VybWluZywgVWxyaWNo|https://orcid.org/0000-0002-1653-7959|https://orcid.org/0000-0003-3250-293X
1000 Hinweis
  • DeepGreen-ID: ac8567897cd24755bf9ea28f0fed4457 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6443592.rdf
1000 Erstellt am 2023-04-27T09:57:55.163+0200
1000 Erstellt von 322
1000 beschreibt frl:6443592
1000 Zuletzt bearbeitet 2023-10-19T15:10:12.796+0200
1000 Objekt bearb. Thu Oct 19 15:10:12 CEST 2023
1000 Vgl. frl:6443592
1000 Oai Id
  1. oai:frl.publisso.de:frl:6443592 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source